Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.62 |
| ▸ | RXRA | P19793 | 6/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17502254 | 0.88 | KCNH2 (1.00) | KCNH2GRIN2BRXRAGRIN1 | |
| Hydrochloric Acid SCHEMBL21802309 | 0.88 | KCNH2 (0.98) | KCNH2GRIN2BRXRAGRIN1 | |
| SCHEMBL17502291 | 0.81 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL17502263 | 0.81 | KCNH2 (1.00) | KCNH2GRIN2BRXRAGRIN1 | |
| Hydrochloric Acid SCHEMBL21802315 | 0.80 | KCNH2 (0.98) | KCNH2GRIN2BRXRAGRIN1 | |
| SCHEMBL19211518 | 0.79 | NOTUM (0.81) | KCNH2GRIN2BRXRAGRIN1 | |
| SCHEMBL17502234 | 0.78 | KCNH2 (1.00) | KCNH2GRIN2BRXRAGRIN1 | |
| SCHEMBL17502277 | 0.77 | KCNH2 (1.00) | KCNH2GRIN2BRXRAGRIN1 | |
| SCHEMBL17502267 | 0.76 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL19211360 | 0.76 | RXRA (1.00) | GRIN2BRXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323021-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323021-B2 | Triazoles as NR2B receptor inhibitors | GRIN2B, GRIN1, GRIN3A | KCNH2 2545/4885GRIN2B 1/4885RXRA 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.